Myelin degeneration induced by mutant superoxide dismutase 1 accumulation promotes amyotrophic lateral sclerosis

Glia. 2019 Oct;67(10):1910-1921. doi: 10.1002/glia.23669. Epub 2019 Jul 10.

Abstract

Myelin is a specialized membrane that wraps around nerve fibers and is essential for normal axonal conduction in neurons. In the central nervous system, oligodendrocytes are responsible for myelin formation. Recent studies have reported pathological abnormalities in oligodendrocytes in human patients with amyotrophic lateral sclerosis (ALS) and a mouse model of ALS expressing the G93A mutation of the human superoxide dismutase 1 (mtSOD1). However, it is unclear whether oligodendrocyte pathology in ALS represents the primary dysfunction induced by mtSOD1 and how mtSOD1 contributes to oligodendrocyte degeneration and ALS pathogenesis. We analyzed GAL4-VP16-UAS transgenic zebrafish selectively expressing mtSOD1 in mature oligodendrocytes. We observed that mtSOD1 directly induced oligodendrocyte degeneration by disrupting the myelin sheath and downregulating monocarboxylate transporter 1 (MCT1), thereby causing spinal motor neuron degeneration. Pathological changes observed in this transgenic zebrafish were similar to the pathology observed in the SOD1G93A mouse model of ALS, which is characterized by expression of mtSOD1 in all cells. In addition, oligodendrocyte dysfunction induced by mtSOD1 was associated with anxiety-related behavioral abnormalities, learning impairments, and motor defects in the early symptomatic stage. We also found that treatment with potassium channel inhibitors rescued behavioral abnormalities without rescuing MCT1 expression, suggesting that myelin disruption induces behavioral abnormalities independently of MCT1. These results indicate that mtSOD1-induced dysfunction of mature oligodendrocytes is sufficient to induce motor neuron degeneration, thus informing future therapeutic strategies targeted at oligodendrocytes in ALS.

Keywords: amyotrophic lateral sclerosis; myelination; oligodendrocytes; superoxide dismutase 1; zebrafish.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis / drug therapy
  • Amyotrophic Lateral Sclerosis / enzymology*
  • Amyotrophic Lateral Sclerosis / pathology
  • Animals
  • Animals, Genetically Modified
  • Cell Death / drug effects
  • Cell Death / physiology
  • Disease Models, Animal
  • Humans
  • Monocarboxylic Acid Transporters / metabolism
  • Motor Neurons / drug effects
  • Motor Neurons / enzymology
  • Motor Neurons / pathology
  • Myelin Sheath / drug effects
  • Myelin Sheath / enzymology*
  • Myelin Sheath / pathology
  • Nerve Degeneration / drug therapy
  • Nerve Degeneration / metabolism*
  • Nerve Degeneration / pathology
  • Neuroprotective Agents / pharmacology
  • Potassium Channel Blockers / pharmacology
  • Superoxide Dismutase-1 / genetics
  • Superoxide Dismutase-1 / metabolism*
  • Zebrafish
  • Zebrafish Proteins / metabolism

Substances

  • Monocarboxylic Acid Transporters
  • Neuroprotective Agents
  • Potassium Channel Blockers
  • SOD1 protein, human
  • Zebrafish Proteins
  • slc16a1b protein, zebrafish
  • Superoxide Dismutase-1